June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Pragmatic usage of Netarsudil: A retrospective chart review from a tertiary care center
Author Affiliations & Notes
  • Nate Goergen
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Meghal Gagrani
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Vikas Gulati
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Deepta Abhay Ghate
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Footnotes
    Commercial Relationships   Nate Goergen, None; Meghal Gagrani, None; Vikas Gulati, None; Deepta Ghate, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1607. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nate Goergen, Meghal Gagrani, Vikas Gulati, Deepta Abhay Ghate; Pragmatic usage of Netarsudil: A retrospective chart review from a tertiary care center. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1607.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Netarsudil (NL), a rho kinase inhibitor, lowers intraocular pressure (IOP) by increasing outflow facility. There is limited literature on the efficacy of NL in secondary glaucomas and as combination therapy. This retrospective study aims to evaluate the prescription patterns, compliance, and efficacy of NL in an academic glaucoma clinic.

Methods : A retrospective chart review was conducted at a tertiary glaucoma clinic for patients prescribed NL from 01/17 to 5/20. Patient demographics, diagnosis, medication history were noted. Baseline IOP was defined as mean IOP of all visits before starting NL while on stable medication regimen. IOP lowering efficacy was calculated as the difference between IOP at the first visit after starting NL and baseline IOP.

Results : 133 patients were prescribed NL during the study period with a mean age of 69 ± 20 years. 59% were females and 74% were white. The indications for NL prescription were IOP over target and/or drug regimen simplification. Of the study subjects, 67 had a diagnosis of a primary glaucoma (84%). NL was always used as part of a combination glaucoma medication regimen (average medication usage 3 ±1). NL prescription was not filled by 17% (n=22) subjects mainly due to cost of medication (n=15). 101 eyes of 76 patients were used for IOP analysis. The mean change in IOP was -1 ± 6 mmHg. IOP decreased in 67% and increased/did not change in 33% patients (Table 1). None of the demographic or ocular factors were statistically associated with the prescription fill status or IOP lowering efficacy. NL was discontinued in 52% (50/96) patients after a mean duration of 78 ± 99 days due to a) surgery due to inability to achieve target IOP (42%) b) allergies or intolerance (30%) c) cost (14%) d) paradoxical rise in IOP (12%).

Conclusions : NL was used as an adjunct 2nd-4th line medication in a tertiary glaucoma practice in Midwestern USA. Of patients prescribed NL, 17% of prescriptions medications went unfilled and NL was discontinued in 52% of patients due to poor efficacy, allergies, and expense. IOP response to NL may be variable in this population with severe complex glaucoma.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×